MX2023006869A - Proteinas de union condicionalmente biespecificas. - Google Patents

Proteinas de union condicionalmente biespecificas.

Info

Publication number
MX2023006869A
MX2023006869A MX2023006869A MX2023006869A MX2023006869A MX 2023006869 A MX2023006869 A MX 2023006869A MX 2023006869 A MX2023006869 A MX 2023006869A MX 2023006869 A MX2023006869 A MX 2023006869A MX 2023006869 A MX2023006869 A MX 2023006869A
Authority
MX
Mexico
Prior art keywords
immune cells
tumor
conditionally
binding proteins
bispecific binding
Prior art date
Application number
MX2023006869A
Other languages
English (en)
Inventor
Tseng-Hui Timothy Chen
Patricia A Culp
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2023006869A publication Critical patent/MX2023006869A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación, en algunos aspectos, proporciona construcciones de activación redirigida biespecífica condicional coestimuladora, o "COBRA coestim", que se administran en un formato de profármaco activo. Tras la exposición a las proteasas tumorales, las construcciones se escinden y se activan, de modo que pueden unirse tanto a los antígenos diana tumorales (TTA) como a las células inmunitarias (p. ej., uno o más tipos de células inmunitarias), para reclutar así células inmunitarias al tumor, lo que da como resultado un tratamiento.
MX2023006869A 2020-12-14 2021-12-14 Proteinas de union condicionalmente biespecificas. MX2023006869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063125267P 2020-12-14 2020-12-14
PCT/IB2021/000868 WO2022130013A1 (en) 2020-12-14 2021-12-14 Conditionally bispecific binding proteins

Publications (1)

Publication Number Publication Date
MX2023006869A true MX2023006869A (es) 2023-08-14

Family

ID=80222325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006869A MX2023006869A (es) 2020-12-14 2021-12-14 Proteinas de union condicionalmente biespecificas.

Country Status (10)

Country Link
EP (1) EP4259663A1 (es)
JP (1) JP2023552865A (es)
KR (1) KR20230131210A (es)
CN (1) CN116964090A (es)
AU (1) AU2021402183A1 (es)
BR (1) BR112023011782A2 (es)
CA (1) CA3201978A1 (es)
CO (1) CO2023009342A2 (es)
MX (1) MX2023006869A (es)
WO (1) WO2022130013A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023164551A1 (en) * 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
EP2987806A3 (en) 2011-08-17 2016-07-13 Glaxo Group Limited Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
AU2018328291B2 (en) 2017-09-08 2022-10-27 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN113286811A (zh) * 2018-07-30 2021-08-20 南加利福尼亚大学 改善过继性细胞疗法的效力和安全性
EP3934762A1 (en) * 2019-03-05 2022-01-12 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins

Also Published As

Publication number Publication date
AU2021402183A1 (en) 2023-07-06
BR112023011782A2 (pt) 2023-10-31
EP4259663A1 (en) 2023-10-18
CO2023009342A2 (es) 2024-01-15
WO2022130013A1 (en) 2022-06-23
AU2021402183A9 (en) 2024-02-08
JP2023552865A (ja) 2023-12-19
CA3201978A1 (en) 2022-06-23
CN116964090A (zh) 2023-10-27
KR20230131210A (ko) 2023-09-12

Similar Documents

Publication Publication Date Title
ZA202002325B (en) Constrained conditionally activated binding proteins
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
CY1114855T1 (el) Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
PH12019502621A1 (en) Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
MX2023006869A (es) Proteinas de union condicionalmente biespecificas.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
MX2023002002A (es) Proteinas de union restringidas activadas de forma condicional.
WO2022051647A3 (en) Constrained conditionally activated binding protein constructs with human serum albumin domains
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
WO2020022898A3 (en) Off-the-shelf cancer vaccines
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
WO2003086041A3 (en) Binding agents and their use in targeting tumor cells
MX2021002500A (es) Anticuerpos y secuencias de nucleotidos novedosos, y sus usos.
ZA202110285B (en) Antibodies and methods of use
MX2022000671A (es) Anticuerpos anti-grp78 y metodo de uso de los mismos.
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
WO2023019121A3 (en) Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
EA202090671A1 (ru) Ограниченные условно активируемые связывающие белки